#	Pagina
attuale pagina	/open-h2020/projects/193398/index.html
-1	/open-h2020/projects/201693/results.html
-2	/open-h2020/projects/221833/index.html
-3	/open-h2020/per-topic/timas/list/index.html
-4	/open-h2020/per-topic/eim/list/index.html
-5	/open-h2020/projects/211150/index.html
-6	/open-h2020/per-topic/crops/list/index.html
-7	/open-h2020/projects/222344/index.html
-8	/open-h2020/per-topic/4/list/index.html
-9	/open-h2020/projects/194440/index.html
-10	/open-h2020/projects/218083/index.html

Opendata, web and dolomites

LuMaSense

A Non-Invasive Test for Guiding Follow–up of Patients with CT-Detected Lung Nodules

Total Cost €

EC-Contrib. €

Partnership

Views

LuMaSense project word cloud

Explore the words cloud of the LuMaSense project. It provides you a very rough idea of what is the project "LuMaSense" about.

transform fund exists health lung utilizing optimization optimal complexity implication combination stages covered portability ldct successful economic undergone distinguish nodule specificity patients auxiliary commercially costly completing market conducting 16 grant usefulness oriented complementary care evaluation false immediately breath prototype mortality placement relies off group urgent countries mature technological erc translated device cancer competitors marketable rationale tool cancerous sensitivity action unnecessary billion front speed screening treatment ct noninvasive reduce stand save positive detected 24 portfolio delay diag technique operation lc transfer healthcare morbidity rate invasive programs clinical spin poc worldwide ip idea powerful plans 96 malignant alone 12 company

Project "LuMaSense" data sheet

The following table provides information about the project.

Coordinator	TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY Organization address address: SENATE BUILDING TECHNION CITY city: HAIFA postcode: 32000 website: www.technion.ac.il contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Israel [IL]
Total cost	150˙000 €
EC max contribution	150˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2014-PoC
Funding Scheme	ERC-POC
Starting year	2015
Duration (year-month-day)	from 2015-06-01 to 2016-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY Organization address address: SENATE BUILDING TECHNION CITY city: HAIFA postcode: 32000 website: www.technion.ac.il contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (HAIFA)	coordinator	150˙000.00

Map

Project objective

This PoC is a commercially-oriented spin-off from our “DIAG-CANCER” ERC project, addressing an urgent clinical need in the field of lung cancer (LC). The rationale behind this PoC is that CT-based LC screening programs are emerging in many countries worldwide. However, the high false positive rate of this technique (96% out of the 24% positive CT findings are non-cancerous) has been a major challenge in front those plans. This is because the CT-detected non-cancerous group has undergone unnecessary invasive procedures that are both costly and associated with significant morbidity and mortality. With this PoC project, we aim to increase the specificity of the LDCT based screening program by utilizing an auxiliary noninvasive breath test to distinguish between malignant and non-cancerous CT findings. The proposed breath test relies on a novel stand-alone device that provide an improved combination of speed, sensitivity, portability, low complexity, easy operation and low production cost. In order to transform our idea and current technology into a marketable device we propose taking several steps: (i) optimization of a prototype device and evaluation of its clinical usefulness through clinical studies; (ii) completing the IP portfolio of the device; and (iii) conducting detailed market research to identify the optimal placement in the healthcare market and possible competitors. After completing these stages, to be covered by the present grant, we propose to proceed to the technology transfer to a mature health care company or through complementary fund to advance the technological plans. If successful, the proposed PoC can be translated immediately into a powerful tool for the management of nodule-positive patients. It will both reduce the rate of unnecessary invasive procedures, and on the other hand, will avoid treatment delay when cancer exists. The economic implication of this action is a significant save of ~$12-16 billion for the healthcare system worldwide.

Publications

List of publications.
year	authors and title	journal	last update
2016	Inbar Nardi-Agmon, Manal Abud-Hawa, Ori Liran, Naomi Gai-Mor, Maya Ilouze, Amir Onn, Jair Bar, Dekel Shlomi, Hossam Haick, Nir Peled Exhaled Breath Analysis for Monitoring Response toÂ Treatment in Advanced Lung Cancer published pages: 827-837, ISSN: 1556-0864, DOI: 10.1016/j.jtho.2016.02.017	Journal of Thoracic Oncology 11/6	2019-07-22

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LUMASENSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LUMASENSE" are provided by the European Opendata Portal: CORDIS opendata.